Drugs / gp100:280-288(288V)
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01176474 | Aug 2010 → Aug 2020 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT01176461 | Aug 2010 → Dec 2016 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00357461 | May 2006 → ? | cutaneous melanoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp100:280-288 (288V) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01176474 ↗ |
| Action | Deplete | “Vaccines made from gp100 peptides may help the body build an effective immune response to kill tumor cells.” NCT00357461 ↗ |
| Modality | Vaccine | “gp100:280-288(288V) peptide vaccine” NCT00357461 ↗ |
| Route | Subcutaneous | “gp100 peptides emulsified in Montanide ISA-51 subcutaneously (SC) on day 1” NCT00357461 ↗ |